Hematological Neoplasms

Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital

**Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital** In the field of cancer treatment, China has achieved groundbreaking success with CAR-T cell therapy, especially in treating relapsed or refractory lymphoma. Today, we share the story of one patient whose life was transformed through this revolutionary treatment Read More

November 12th,2024 patient story , CAR-T , Lymphoma

New Breakthrough in CAR-T Cell Research in China: Type 2 T Cell Function Supports Long-term Leukemia Remission

#### New Breakthrough in CAR-T Cell Research in China: Type 2 T Cell Function Supports Long-term Leukemia Remission #CAR-T #Leukemia #Type2TCells #ALL #GATA3 In recent years, China has achieved significant progress in CAR-T cell therapy, particularly in treating acute lymphoblastic leukemia (ALL). CD19-targeted CAR-T cell therapy has provided new hope for curing patients with relapsed or refractory Read More

November 7th,2024 Leukemia , CAR-T

**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)**

**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)** #CAR-T #DLBCL #Lymphoma #CARTtherapy #RRDLBCL #Patientstory #CD19 In the field of cancer treatment, China has made remarkable strides in CAR-T cell therapy, especially in the fight against relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Read More

November 7th,2024 CAR-T , Lymphoma , patient story

APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL)

### APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL) #CAR-T #CNSL #ASCT #APBMT2024 #CARTtherapy #CentralNervousSystemLymphoma #Lymphoma #RRCNSL #APBMT In the treatment of relapsed or refractory central nervous system lymphoma (R/R CNSL), Chinese CAR-T therapy is pioneering new directions worldwide. Conventional treatments for this disease have shown limited effectiveness, particularly when autologous stem Read More

November 7th,2024 CAR-T , Lymphoma

Groundbreaking Chinese CAR-T Research: CD5 CAR-T Therapy Brings New Hope for Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)

Groundbreaking Chinese CAR-T Research: CD5 CAR-T Therapy Brings New Hope for Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) Relapsed or refractory acute T-cell lymphoblastic leukemia (r/r T-ALL) has long lacked effective treatment options, with a poor prognosis. Although CD7 CAR-T therapy has shown some efficacy, many patients experience relapse due to CD7 antigen loss. #CAR-T #TALL #ALL #CARTtherapy #leukemia Read More

November 6th,2024 Leukemia , CAR-T

Breakthrough in China’s CAR-T Therapy for Treating Relapsed B-ALL: Donor-Derived CD19 CAR-T Shows Long-Term Survival Advantage

**Breakthrough in China’s CAR-T Therapy for Treating Relapsed B-ALL: Donor-Derived CD19 CAR-T Shows Long-Term Survival Advantage** #CAR_TTherapy #B_ALL #DonorCAR_T #CAR_T #ALL #ChinaCART #CD19 #alloHSCT In recent years, China has made significant strides in CAR-T cell therapy, particularly in treating B-cell acute lymphoblastic leukemia (B-ALL). Donor-derived CAR-T therapy has shown promising efficacy for B-ALL patients who Read More

November 6th,2024 Leukemia , CAR-T

The Rise of China’s CAR-T Therapy: New Hope for Multiple Myeloma Patients

**The Rise of China’s CAR-T Therapy: New Hope for Multiple Myeloma Patients** #CARTTherapy #CART #MultipleMyeloma #BloodCancer #patientstory China’s CAR-T cell therapy has emerged as a highly effective and proactive option for treating relapsed and refractory multiple myeloma, bringing new hope to patients facing limited treatment options. This innovative therapy has shown significant effectiveness in clinical Read More

November 5th,2024 Myeloma , CAR-T , patient story

New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma

**New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma** #BCMA #CD27#CARTCellTherapy #RRMM #MM #MultipleMyeloma #CART Relapsed and refractory multiple myeloma (RRMM) is a challenging blood cancer that poses significant obstacles for patients. Although several BCMA (B-cell maturation antigen) targeting CAR-T cell therapies have been developed, achieving Read More

November 5th,2024 Myeloma

CAR-T Cell Therapy as a New Option for Treating Multiple Myeloma

**CAR-T  Cell Therapy as a New Option for Treating Multiple Myeloma** “CAR-T cell therapy has now become a new option for treating patients with relapsed and refractory multiple myeloma, with hopes of changing the difficult situation in myeloma treatment where treatments are either ineffective or unavailable,” said Jin Jie, Director of the Hematology Department at the Read More

November 4th,2024 Myeloma , CAR-T

China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL)

China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL)  #CARTTherapy #Leukemia #ChildhoodCancer #ALL #CART #AcuteLymphoblasticLeukemia #Patientstory China’s CAR-T cell therapy is emerging as a beacon of hope in the fight against cancer, bringing unprecedented treatment possibilities. As a precise cellular immunotherapy, CAR-T therapy enhances the cancer-fighting abilities of T-cells through genetic editing technology, Read More

November 1st,2024 Leukemia , CAR-T , patient story

China’s CAR-T Therapy as a Beacon of Hope: A New Light for Multiple Myeloma Patients

**China’s CAR-T Therapy as a Beacon of Hope: A New Light for Multiple Myeloma Patients** #CAR-TTherapy #MultipleMyeloma #PatientStory #CancerSurvivor In recent years, CAR-T cell therapy in China has spearheaded a revolution in hematologic cancer treatment. This innovative immunotherapy has brought a glimmer of hope to many patients, especially those with relapsed and refractory cases who Read More

October 31st,2024 Myeloma , CAR-T

China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)

**China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)** #CLL1CART #AML #Leukemia #CART #CARTtherapy #AcuteMyeloidLeukemia #CLL1 #CD371 In recent years, China’s rise in the field of medical innovation has been remarkable, especially with breakthroughs in cancer and hematologic malignancy treatments that are drawing global attention. Today, we are introducing a cutting-edge treatment from China—donor-derived CLL-1 Read More

October 29th,2024 Leukemia , CAR-T